Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being finalized with targeted launch late-summer 2024 Once-daily NE3107 formulation expected to be available early 2025 and will be used for Phase 3 trial in Alzheimer’s Disease Phase 3 trial for BIV201 in preparation following FDA feedback with guidance on development path; program delayed pending partnership fundi
Denmark
Portugal
United-states
Copenhagen
Køavn
Lisbon
Lisboa
Gothenburg
Vastra-gotalands-lan
Sweden
Americans
Bruce-mackle